tiprankstipranks
Trending News
More News >

Kalaris Therapeutics Adjusts Annual Meeting Schedule

Story Highlights
Kalaris Therapeutics Adjusts Annual Meeting Schedule

Don’t Miss TipRanks’ Half-Year Sale

Kalaris Therapeutics ( (KLRS) ) has provided an announcement.

Kalaris Therapeutics, Inc. has announced that its 2025 annual meeting of stockholders will be held on August 12, 2025, a change of more than 30 days from the previous year’s meeting. Stockholders are required to submit proposals by June 30, 2025, to be included in the proxy materials, and must comply with the company’s by-laws and SEC rules. This adjustment in the meeting schedule signifies a shift in the company’s operational timeline, potentially impacting stakeholder engagement and decision-making processes.

The most recent analyst rating on (KLRS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kalaris Therapeutics stock, see the KLRS Stock Forecast page.

Spark’s Take on KLRS Stock

According to Spark, TipRanks’ AI Analyst, KLRS is a Underperform.

AlloVir’s stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.

To see Spark’s full report on KLRS stock, click here.

More about Kalaris Therapeutics

Average Trading Volume: 48,458

Technical Sentiment Signal: Sell

Current Market Cap: $43.02M

See more insights into KLRS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1